The burgeoning biotech industry is built on modern scientific elements principally comprised of: genomics, genetics, immunology, molecular targeting and cell therapy. These therapeutics are increasingly designed to interact with a specific biochemical target in order to increase efficacy, reduce side effects, and produce an otherwise unattainable therapeutic benefit. These biotech drugs include: peptides, proteins, antibodies, vaccines, gene therapy and cell therapy. Most of these treatments are intravenous or injection, although R&D is taking place to find convenient oral or transdermal substitutes. The biotech sector cuts across industry, research institutes, academia, and hospitals across the world.
Ferghana advises its clients on strategic Partnerships, Acquisitions and Divestments, as well as on creative Financings, since these elements are all critical to the healthy future and growth of biotech companies.
Ferghana has evolved its Biotechnology franchise with a focus on both enabling technology companies and on innovative therapeutic companies utilizing these following disciplines across all therapeutic categories of drugs and vaccines: